Literature DB >> 21821379

A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Traci R Rieckmann1, Anne E Kovas, Bentson H McFarland, Amanda J Abraham.   

Abstract

Despite evidence that buprenorphine is effective and safe and offers greater access as compared with methadone, implementation for treatment of opiate dependence continues to be weak. Research indicates that legal and regulatory factors, state policies, and organizational and provider variables affect adoption of buprenorphine. This study uses hierarchical linear modeling to examine National Treatment Center Study data to identify counselor characteristics (attitudes, training, and beliefs) and organizational factors (accreditation, caseload, access to buprenorphine, and other evidence-based practices) that influence implementation of buprenorphine for treatment of opiate dependence. Analyses showed that provider training about buprenorphine, higher prevalence of opiate-dependent clients, and less treatment program emphasis on a 12-step model predicted greater counselor acceptance and perceived effectiveness of buprenorphine. Results also indicate that program use of buprenorphine for any treatment purpose (detoxification, maintenance, and/or pain management) and time (calendar year in data collection) was associated with increased diffusion of knowledge about buprenorphine among counselors and with more favorable counselor attitudes toward buprenorphine.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821379      PMCID: PMC3486698          DOI: 10.1016/j.jsat.2011.05.005

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  66 in total

1.  Counselor assessments of training and adoption barriers.

Authors:  Norma G Bartholomew; George W Joe; Grace A Rowan-Szal; D Dwayne Simpson
Journal:  J Subst Abuse Treat       Date:  2007-04-16

2.  Assessing the organizational social context (OSC) of mental health services: implications for research and practice.

Authors:  Charles Glisson; John Landsverk; Sonja Schoenwald; Kelly Kelleher; Kimberly Eaton Hoagwood; Stephen Mayberg; Philip Green
Journal:  Adm Policy Ment Health       Date:  2007-12-18

3.  Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers.

Authors:  Carrie B Oser; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2007-11       Impact factor: 2.582

4.  Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Am J Addict       Date:  2007 Sep-Oct

5.  Does state certification or licensure influence outpatient substance abuse treatment program practices?

Authors:  Jamie F Chriqui; Yvonne Terry-McElrath; Duane C McBride; Shelby Smith Eidson; Curtis J VanderWaal
Journal:  J Behav Health Serv Res       Date:  2007-06-26       Impact factor: 1.505

6.  Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.

Authors:  Pamela Vergara-Rodriguez; Mary Jo Tozzi; Michael Botsko; Vijay Nandi; Frederick Altice; James E Egan; Patrick G O'Connor; Lynn E Sullivan; David A Fiellin
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

7.  Advancing performance measures for use of medications in substance abuse treatment.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Frank McCorry; Amanda Gmyrek; Mady Chalk; David R Gastfriend; Suzanne Gelber Rinaldo; Joann Albright; Victor A Capoccia; Alex H S Harris; Henrick J Harwood; Pamela Greenberg; Tami L Mark; Huong Un; Marla Oros; Mark Stringer; James Thatcher
Journal:  J Subst Abuse Treat       Date:  2010-10-08

8.  Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists.

Authors:  Cindy Parks Thomas; Sharon Reif; Sayeda Haq; Stanley S Wallack; Alexander Hoyt; Grant A Ritter
Journal:  Psychiatr Serv       Date:  2008-08       Impact factor: 3.084

9.  Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.

Authors:  Alexander Y Walley; Julie K Alperen; Debbie M Cheng; Michael Botticelli; Carolyn Castro-Donlan; Jeffrey H Samet; Daniel P Alford
Journal:  J Gen Intern Med       Date:  2008-09       Impact factor: 5.128

10.  Attitudes toward buprenorphine and methadone among opioid-dependent individuals.

Authors:  Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Shannon Gwin Mitchell; James A Peterson; Heather Schacht Reisinger; Michael H Agar; Barry S Brown
Journal:  Am J Addict       Date:  2008 Sep-Oct
View more
  19 in total

1.  Counselor Attitudes Toward Contingency Management for Substance Use Disorder: Effectiveness, Acceptability, and Endorsement of Incentives for Treatment Attendance and Abstinence.

Authors:  Lydia Aletraris; Jeff S Shelton; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2015-05-07

2.  Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse.

Authors:  Tara Malekshahi; Nina Tioleco; Nahima Ahmed; Aimee N C Campbell; Deborah Haller
Journal:  J Subst Abuse Treat       Date:  2014-07-23

3.  Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.

Authors:  Hannah K Knudsen; Jamie L Studts
Journal:  J Behav Health Serv Res       Date:  2019-01       Impact factor: 1.505

4.  Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens; Jamie L Studts
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

5.  Climate for innovation, 12-step orientation, and tobacco cessation treatment.

Authors:  Jessica L Muilenburg; Tanja C Laschober; Lillian T Eby
Journal:  J Subst Abuse Treat       Date:  2013-11-12

6.  Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  Subst Abus       Date:  2015-04-20       Impact factor: 3.716

7.  Assessing Differences in the Availability of Opioid Addiction Therapy Options: Rural Versus Urban and American Indian Reservation Versus Nonreservation.

Authors:  Katherine A Hirchak; Sean M Murphy
Journal:  J Rural Health       Date:  2016-03-14       Impact factor: 4.333

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  Organizational factors as predictors of tobacco cessation pharmacotherapy adoption in addiction treatment programs.

Authors:  Jessica L Muilenburg; Tanja C Laschober; Lillian T Eby
Journal:  J Addict Med       Date:  2014 Jan-Feb       Impact factor: 3.702

10.  Sustained, new, never, and discontinued tobacco cessation services adopters.

Authors:  Lillian T Eby; Tanja C Laschober; Jessica L Muilenburg
Journal:  J Subst Abuse Treat       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.